Hyundai Bioland

052260 · KOSDAQ · Materials · SMALL CAP

Revenue up 9.2% in FY2025.

Hyundai Bioland reported consolidated results for FY2025: revenue of US$89.4M (+9.2% year on year), operating profit of US$8.71M (−22.3% year on year) and net income of US$173K (−95.6% year on year).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-02-05· RCEPT 20260205900897

US$89.4MRevenue
+9.2%Revenue vs a year earlier
US$8.71MOperating profit

Converted at 1 USD ≈ ₩1,460.11 (filing-date rate, 2026-02-05 close)

What happened

Hyundai Bioland reported consolidated results for FY2025: revenue of US$89.4M (+9.2% year on year), operating profit of US$8.71M (−22.3% year on year) and net income of US$173K (−95.6% year on year).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$89.4M
Revenue vs a year earlier+9.2%
Operating profitUS$8.71M
Net incomeUS$173K
PeriodFY2025 (consolidated)
Filed2026-02-05, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260205900897 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-05 (KST). · Converted at 1 USD ≈ ₩1,322 (rate of 2026-10-22).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.